Archimedes Tech SPAC Partners II Co. Ordinary Shares (ATII)vsChurchill Capital Corp XI Class A Ordinary Shares (CCXI)
ATII
Archimedes Tech SPAC Partners II Co. Ordinary Shares
$10.65
-0.28%
FINANCIAL SERVICES · Cap: $315.13M
CCXI
Churchill Capital Corp XI Class A Ordinary Shares
$10.22
0.00%
FINANCIAL SERVICES · Cap: $3.74B
Smart Verdict
WallStSmart Research — data-driven comparison
CCXI leads profitability with a 0.0% profit margin vs 0.0%. CCXI earns a higher WallStSmart Score of 32/100 (F).
ATII
Avoid32
out of 100
Grade: F
CCXI
Avoid32
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 549.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% earnings growth
0.0% margin — thin
ROE of -47.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ATII
ATII has a balanced fundamental profile.
Bull Case : CCXI
The strongest argument for CCXI centers on Revenue Growth. Revenue growth of 549.0% demonstrates continued momentum.
Bear Case : ATII
The primary concerns for ATII are P/E Ratio, Revenue Growth, EPS Growth.
Bear Case : CCXI
The primary concerns for CCXI are EPS Growth, Profit Margin, Return on Equity.
Key Dynamics to Monitor
ATII profiles as a value stock while CCXI is a hypergrowth play — different risk/reward profiles.
CCXI is growing revenue faster at 549.0% — sustainability is the question.
ATII generates stronger free cash flow (-45,072), providing more financial flexibility.
Monitor SHELL COMPANIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ATII scores higher overall (32/100 vs 32/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Archimedes Tech SPAC Partners II Co. Ordinary Shares
FINANCIAL SERVICES · SHELL COMPANIES · USA
Archimedes Tech SPAC Partners II Co. is a special purpose acquisition company strategically focused on merging with high-potential technology firms that demonstrate strong growth prospects. With a seasoned management team possessing extensive industry knowledge, the company aims to forge partnerships that enhance operational efficiencies and drive shareholder value. By aligning with disruptive innovators within the fast-evolving technology landscape, Archimedes is well-positioned to capitalize on emerging market opportunities, making it an attractive investment proposition for institutional investors seeking exposure to transformative technology sectors.
Visit Website →Churchill Capital Corp XI Class A Ordinary Shares
FINANCIAL SERVICES · SHELL COMPANIES · USA
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.
Compare with Other SHELL COMPANIES Stocks
Want to dig deeper into these stocks?